Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 4/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24784940 | 0.81 | KRAS (0.34) | KRASCNR2NOTUM | |
| SCHEMBL29297523 | 0.79 | CNR2 (0.32) | CNR2 | |
| SCHEMBL25827014 | 0.77 | NOS3 (0.38) | KRASCNR2 | |
| SCHEMBL25811660 | 0.77 | KRAS (0.33) | KRAS | |
| SCHEMBL24785502 | 0.77 | KRAS (0.35) | KRAS | |
| SCHEMBL26059013 | 0.77 | BACE1 (0.31) | — | |
| SCHEMBL18310634 | 0.76 | KLKB1 (0.33) | — | |
| SCHEMBL21733359 | 0.75 | HSP90AA1 (0.35) | — | |
| SCHEMBL22062893 | 0.71 | HTR1D (0.37) | — | |
| SCHEMBL22062963 | 0.71 | NOS3 (0.33) | KRAS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226113-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | KUMQUAT BIOSCIENCES INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240226113-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | KUMQUAT BIOSCIENCES INC. | 2024-07-11 | — | — | US | disclosed |
| WO-2023125989-A1 | QUINAZOLINE COMPOUND AND APPLICATION THEREOF | 上海医药集团股份有限公司 | 2023-07-06 | — | — | WO | disclosed |
| US-11236068-B2 | Fused ring compounds | GENENTECH, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-20210230142-A9 | FUSED RING COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2021-07-29 | — | — | US | disclosed |
| US-20200181118-A1 | FUSED RING COMPOUNDS | GENENTECH INC (US) | 2020-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210230142-A9 | FUSED RING COMPOUNDS | KRAS, NRAS, HRAS | KRAS 1/4885CNR2 3552/4885NOTUM 4604/4885 |
| US-20240226113-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TP53, HRAS, KRAS | KRAS 3/4885CNR2 1704/4885NOTUM 4193/4885 |
| US-20200181118-A1 | FUSED RING COMPOUNDS | KRAS, NRAS, HRAS | KRAS 1/4885CNR2 3552/4885NOTUM 4604/4885 |
| US-11236068-B2 | Fused ring compounds | KRAS, NRAS, HRAS | KRAS 1/4885CNR2 3552/4885NOTUM 4604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.